Immunosuppressants: JC virus encephalopathy. Rare but fatal.
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007555:Isoxazoles / Q000009:adverse effects; D007577:JC Virus / Q000187:drug effects; D000077339:Leflunomide; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D009173:Mycophenolic Acid / Q000009:adverse effects; D000069442:Natalizumab; D000069283:Rituximab; D020123:Sirolimus / Q000009:adverse effects; D016559:Tacrolimus / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D000069442:Natalizumab; D000069283:Rituximab; D000077339:Leflunomide; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus; C472181:efalizumab